Heart failure

We want to help prevent and treat heart failure, a leading cause of death


Congestive heart failure, also known as heart failure (HF) is a chronic and progressive disease1 that affects 64 million people worldwide.2 In the US, fifty percent of patients will die within five years of diagnosis,3 and it is becoming noticeably more prevalent with our aging population.4 Heart failure is the leading cause of hospitalisation for those over the age of 65 and also impacts quality of life and overall health outcomes.5,6 Despite medical advances, it remains as life-threatening as some of the most common types of cancer in both men (prostate and bladder cancers) and women (breast cancers).7

 

Addressing heart failure and other CVRM diseases

As research continues to unveil further insights into the reality of the comorbidities of heart failure, it is vital that we consider the patient as a whole, not merely focusing on one disease, and adapt our research, development, and treatments accordingly.

We dare to do things differently and challenge ourselves to better understand how our portfolio can be used to help address multiple risk factors or comorbidities across cardiovascular, renal, metabolic diseases (CVRM). We endeavour to support heart failure patients throughout their journey, ease the challenges they endure and ultimately reduce the heart failure risk by revolutionising the current care possibilities provided.

 

The patient experience


Facing daily life with emotional worry and physical burden

Patients suffering from chronic heart failure disease often feel daily activities, including even carrying groceries, are energy-depleting tasks. Alongside the physical challenges heart failure poses, patients may become tormented with worry, as they fear normal tasks could worsen their condition or even threaten their life. To add to patients’ pain, individuals suffering from heart failure may furthermore be impacted by interconnected cardiovascular, renal, or metabolic diseases.17 


64 million

people are impacted by heart failure worldwide2

#1 cause of hospitalisation

for those over the age of 65 is heart failure5

4 in 10

chronic heart failure patients who take RAAS inhibitors at some point develop hyperkalaemia15


25-40%

of people with T2D will develop chronic or acute heart failure21

5-year survival rate

of both men and women with heart failure has been shown to be lower than some of the most common cancers in both men (prostate and bladder cancers) and women (breast cancers)7 in Scotland7


Our commitment


Today, we are focusing on developing our therapies to help reach even more patients affected by heart failure. Not only do we strive to bring the right treatment and introduce new life-changing medicines for patients suffering from heart failure, we also dedicate our efforts to bringing awareness to the forefront of our ambition to highlight the importance of tackling one of the leading causes of death and push the boundaries of heart failure treatment guidelines. 


Our people

AstraZeneca has one of the richest clinical pipelines today in the heart failure area in terms of prevention and treatment of various subtypes of heart failure. Our ambition is indeed to eventually reverse the disease and to eradicate heart failure.

Li-Ming Gan Medical Science Director, Early Clinical Development (Cardiovascular and Metabolism), BioPharmaceuticals R&D

Discover more about CVRM

References

  1. American Heart Association. What is Heart Failure?; 2017 [cited 2019 Sep 5]. Available from: URL: https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure.
  2. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211-1259.
  3. Mozaffarian D, et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016;133(4):e38-360.
  4. Savarese G, et al. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017;3(1):7-11.
  5. Azad N, Lemay G. Management of chronic heart failure in the older population. J Geriatr Cardiol. 2014;11(4):329–37. doi:10.11909/j.issn.1671-5411.2014.04.008
  6. European Society of Cardiology (ESC). One in five people will develop heart failure. ScienceDaily. 2015. Available from: www.sciencedaily.com/releases/2015/05/150505111934.htm [Accessed June 2018].
  7. Mamas MA, et al. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. Eur J Heart Fail. 2017;19(9):1095–104.
  8. Gheorghiade M, et al. Navigating the crossroads of coronary artery disease and heart failure. Circulation. 2006;114(11):1202–13.
  9. Faden G, et al. The increasing detection of asymptomatic left ventricular dysfunction in patients with type 2 diabetes mellitus without overt cardiac disease: data from the SHORTWAVE study. Diabetes Res Clin Pract. 2013;101(3):309-16.
  10. Seferović PM et al. Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018; 20(5):853–72.
  11. House AA, et al. Heart failure in chronic kidney disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019;95(6):1304–17.
  12. Segall L, et al. Heart failure in patients with chronic kidney disease: A systematic integrative review. Biomed Res Int. 2014;2014:937398.
  13. National Kidney Foundation. "Clinical Update on Hyperkalemia." 2014. Accessed 16 May 2018. https://www.kidney.org/sites/default/files/02-10-6785_HBE_Hyperkalemia_Bulletin.pdf.
  14. Kuijvenhoven MA, Haak EA, Gombert-Handoko KB, Crul M. Evaluation of the concurrent use of potassium-influencing drugs as risk factors for the development of hyperkalemia. Int J Clin Pharm. 2013 Dec;35(6):1099-104.
  15. Thomsen RW, et al. Elevated Potassium Levels in Patients with Congestive Heart Failure: Occurrence, Risk Factors, and Clinical Outcomes: A Danish Population-Based Cohort Study. J Am Heart Assoc. 2018 May 22;7(11).
  16. Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015 Sep;21 (11 Suppl):S212-S220.
  17. Arnold SV, et al. Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. Diabetes Obes Metab. 2018;20(8):2000–3.
  18. Bytyçi I, Bajraktari G. Mortality in heart failure patients. Anatol J Cardiol. 2015;15(1):63–8.
  19. Lawson CA et al. Comorbidity health pathways in heart failure patients: A sequences-of-regressions analysis using cross-sectional data from 10,575 patients in the Swedish Heart Failure Registry. PLoS Med 2018; 15(3):e1002540.
  20. American Heart Association. Warning signs of Heart Failure. 2017. Accessed 12 Sept 2019. https://www.heart.org/en/health-topics/heart-failure/warning-signs-of-heart-failure
  21. Rosano GM, et al. Heart failure in patients with diabetes mellitus. Card Fail Rev. 2017;3(1):52-55.

Veeva ID: Z4-20768

Date of preparation: October 2019

Date of expiry: October 2021